Dublin, Oct. 18, 2021 (GLOBE NEWSWIRE) -- The "PV (Pharmacovigilance) Audit Strategy Planning - A Practical Approach to Design and Implementation" training has been added to ResearchAndMarkets.com's offering.
In this two-day workshop conference, we will review the EMA and FDA requirements regarding Risk-Based Audits of the PV system and Quality System.
The European Medicines Agency's (EMA) Guideline on good pharmacovigilance practices (GVP), Module IV requires that risk-based audits of the quality system be performed at regular intervals to assure that it complies with the established quality requirements and to determine its effectiveness.
It includes an audit of the pharmacovigilance system which is covered by the quality system. The GVP Modules are applicable to EU-based companies and any company marketing medicinal products on a global basis. The legally required risk-based audit strategy shall cover all PV processes and tasks undertaken by or delegated to other departments, MAH affiliates, and third parties such as distributors, external service providers, partners (the PV Universe). The PV Audit Strategy Plan is used to prepare the PV audit program, i.e. annual PV Audit Schedule.
The course will focus on the design of the PV audit strategy, identification of the PV processes and entities subject to PV audit (define the PV audit universe), development of risk assessment methodology, development of procedures/tools to monitor PV processes and activities, and implementation of the PV audit strategy plan. Additionally, we will review methods of quality oversight and management of third parties performing PV activities.
Upon completing this course, participants should be able to:
Understand the legal requirements and health authority expectations for a risk-based audit program and current interpretation. Plan, develop and implement the PV Audit Strategy Plan, which includes the following processes:
Develop a high-level PV audit strategy
Identify the PV activities and processes subject to PV audit
Develop risk assessment criteria
Identify the PV audit universe - entities subject to PV audit
Categorize the entities subject to PV audit
Perform risk assessments
Prioritize entities for an audit according to relative risk
Prepare a 3-5 year PV audit plan
Identify procedures/tools to monitor PV quality of third parties
Key Topics Covered:
Review of FDA and EMEA requirements for risk-based PV audits
The pharmacovigilance system and the quality system
Strategic level audit planning
PV activities and processes subject to PV audit
Risk assessment criteria
The PV audit universe - all entities subject to PV audit
Safety data exchange agreements (SDEAs) and vendor contracts
Stability (shelf-life) studies
Categorization of the entities (PV Audit Universe)
Prioritization of entities for an audit according to relative risk
3-5 year PV audit plan
Procedural documents, e.g. SOPs
Identify procedures/tools to monitor PV quality for oversight of third parties
Q & A
For more information about this training visit https://www.researchandmarkets.com/r/2vg020
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900